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Summary
Objective: To assess the infection risk of splenectomized persons with hemoglobinopathies in
Australia.
Methods: This was an Australia cohort study of infections and vaccinations in 63 patients with
hemoglobinopathies followed longitudinally from 1967 to 2006, and an investigation into the risk
factors for poor outcome.
Results: There were 28 cases of bacterial infection that necessitated hospitalization in the
cohort, resulting in an incidence of 1.4 bacterial infections per 100 patient-years. There was one
death (1.6%) as a direct result of bacterial infection. Hepatitis C was diagnosed in 28 patients
(44%). The spectrum of infection included pneumonia (6/28), cellulitis (6/28), bacteremia (4/
28), and skin abscess (3/28). Notably, Klebsiella species organisms were isolated in 9/28 cultures.
Conclusions: Infectious complications in this group of patients cause serious morbidity and
mortality. This cohort may be a target for novel preventive strategies such as more immunogenic
vaccines, patient registries, and/or education programs.
# 2008 International Society for Infectious Diseases. Published by Elsevier Ltd. All rights reserved.* Corresponding author. Tel.: +61 2 9845 6255; fax: +61 2 9893 8659.
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Hemoglobinopathies arise from common genetic defects with
an estimated 300 000 affected infants born each year with
homozygous thalassemia syndromes (30%) or sickle cell ane-
mia (70%). The mainstay of management of thalassemiaPublished by Elsevier Ltd. All rights reserved.
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apy. Splenectomy has been a common management strategy
for reducing regular transfusion requirements, iron overload,
and extramedullary hematopoiesis in patients with hemoglo-
binopathies (e.g., thalassemia major, sickle thalassemia) and
Diamond—Blackfan syndrome. Infections are the secondmost
common cause of morbidity and mortality (12—46%) in
patients with thalassemia1 after cardiac complications of
iron overload.2 Encapsulated bacteria such as Streptococcus
pneumoniae, Neisseria meningitidis, and Haemophilus
influenzae type b (Hib) have previously been implicated
in overwhelming post-splenectomy infection (OPSI), with
considerable variation in the pathogens reported in interna-
tional cohorts of iron-overloaded individuals.1—4 Specific
vaccinations including 23-valent pneumococcal polysacchar-
ide vaccine (23PPV) have been advocated as preventative
measures for splenectomized patients to minimize severe
infection risk from S. pneumoniae.5,6 The spectrum of infec-
tions and effectiveness of vaccination strategies have
not previously been reported in splenectomized patients in
Australia.
Patients and methods
The cohort included 64 transfusion-dependent patients with
a hemoglobinopathy. The patients had been followed as
adults through a tertiary referral hospital in Sydney, Austra-
lia, between July 1967 and December 2006. Information on
demographics, hematological diagnosis (based on findings of
hemoglobin electrophoresis and/or molecular defect, blood
test, and bone marrow biopsy), age at diagnosis, surgical
interventions (including splenectomy), iron chelation ther-
apy, vaccination status, and clinical infections were derived
from the medical records (1967—2006). Vaccination records
were also sourced from a computerized hospital pharmacy
database established in 1999.Table 1 Cohort characteristics (N = 63)
Male
Median age, years
Median follow-up, years
Patient-years
Thalassemia major
Sickle thalassemia
Diamond—Blackfan syndrome
Thalassemia intermedia
Sickle cell anemia
Mediterranean descent
Asian descent
Desferrioxamine
Splenectomized
Secondary complications of iron overload
Cardiomyopathy
Diabetes mellitus
Total deaths
Death from cardiovascular complication
Death from infection or infection-related
Death from other causes
Results are n (%) unless otherwise stated. OPSI, overwhelming post-spAll infections were defined by the Centers for Disease Con-
trol and Prevention (CDC) criteria.7 The diagnosis of infection
was based on clinical presentation and evidence from physical
examinations and imaging studies. Infection was confirmed by
isolation of pathogens from blood, cerebrospinal fluid, urine,
wound, or body fluid specimens, or antibody/antigen assay
from serum. Data regarding clinical presentation, investiga-
tions, and potential risk factors were reviewed together.
Patients were grouped into surgically splenectomized or
non-splenectomized,andalsoas vaccinatedornon-vaccinated
based on vaccination records. The number of infections per
100 patient-years of follow-up was calculated yielding an
adjusted infection rate. Univariate analysis of categorical
variables was performed using the Chi-square test with calcu-
lation of 95% confidence intervals and p-values. Multivariate
logistic regression analysis was performed using SAS 9.1 (SAS
Institute Inc., 2003) for determination of those risk factors
associated with infection outcomes. A p-value of <0.05 was
considered statistically significant.
Consent from patients was obtained by their hematologist
for access to records, and ethical approval was obtained
from the South Eastern and Illawarra Area Health Service
Research Ethics Committee.
Results
Sixty-four adult patients were assessed. However, one
patient’s medical records could not be accessed and hence
this patient was not included in the analysis. Therefore the
cohort included a total of 63 patients (Table 1).
There was one documented case of OPSI in this cohort
resulting in the death of the patient. The patient had been
splenectomized for Diamond—Blackfan syndrome. No record
of 23PPV vaccination was found in themedical records and his
vaccination status remains uncertain. The patient had been
undergoing transfusions for approximately 20 years, was on32 (51)
31.61 (range 18.81—55.30)
30 (range 14.42—54.75)
1960 years
55 (87)
3 (5)
2 (3)
2 (3)
1 (2)
56 (89)
7 (11)
57 (90)
50 (79)
50 (79)
18 (29)
12 (19)
7 (11)
3 (5)
2 (3) (cause: OPSI and hepatoma)
2 (3) (cause: intra-operative bleed and CVA)
lenectomy infection; CVA, cerebrovascular accident.
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698 A.R. Yapp et al.desferrioxamine (DFO) at the time of death, had a history of
diabetes mellitus secondary to iron overload, and had had no
blood-borne infections.
Splenectomy
There were 0.32 deaths per 100 years of follow-up in the
surgically splenectomized group versus 0.51 deaths per 100
years of follow-up from diagnosis in the non-splenectomized
group ( p-value not significant).
Vaccination
Forty-three of the cohort were documented to have received
pneumococcal vaccination. Of the 43 persons who received
23PPV, 40 were splenectomized. The rate of 23PPV admin-
istration in the splenectomized group (2.6 cases per 100
person-years) was significantly higher ( p = 0.0469) than that
in non-splenectomized group (0.8 cases per 100 person-
years). The relative rate (RR) of 23PPV in the splenectomized
group was 3.2864 (95% confidence interval 1.0166—10.6228).
Six of the patients had been administered a Hib vaccine.
There were 27 documented vaccinations of meningococcal
vaccine since 1999, three of which involved administration of
polysaccharide preparations and 24 the use of conjugated
vaccine preparations. Annual influenza vaccines were com-
monly performed by family physicians, though records were
often missing or incomplete. Eighteen (31%) of 58 hepatitis B
surface antigen (HBsAg)-negative patients were recorded as
having received hepatitis B vaccine since 1982.
Bacterial infection
Within this study, 21 (33%) patients were documented as
having had one or more clinically significant bacterial infec-
tions (Table 2). The review demonstrates 28 clinically sig-
nificant infections over 1960 years equating to an incidence
of 1.4 infections per 100 patient years.
Overall rates of bacteremia were 0.2 per 100 years of
adult patient follow-up. The rate of invasive pneumococcal
disease was calculated as 0.05 cases per 100 years of adult
follow-up with no statistical difference between the sple-
nectomized and non-splenectomized groups.
Blood-borne viruses
The infection rate for blood-borne viruses (hepatitis C,
hepatitis B, and HIV; Table 3) was 1.7 per 100 person-yearsTable 3 Blood-borne viral infections (N = 30 patients)
Splenectomized Non-splenectomized Total
Hepatitis B 5
Acute 3 1 4
Chronic 1 0 1
Hepatitis C 23 5 28
HIV 1 0 1
Total 28 6 34a
a There were four patients with both hepatitis B and C.
Infection in splenectomized patients, Australia 699in splenectomized patients and 1.5 per 100 person-years in
the non-splenectomized patients ( p-value not significant).
Four (80%) of five patients were recorded to have acute
infections with hepatitis B, diagnosed after starting transfu-
sion and prior to routine blood supply screening for HBsAg or
hepatitis B core antibody (HBcAb). The one remaining case of
hepatitis B was acquired prior to transfusion, and the patient
had a clinical history and serum hepatitis B virus antibodies
and antigen results consistent with being chronically infected
with hepatitis B. A hepatoma secondary to hepatitis C infec-
tion was the cause of death in one patient and no other cause
was identified.
One patient, who had been transfused in the years before
serological testing for HIV, was recorded to be HIV-positive
and was alive at the time of the conclusion of this study.
Discussion
With the exception of heart failure, infection continues to be
the leading cause of mortality and morbidity in patients with
hemoglobinopathies, especially thalassemia.2 However, sur-
vival has improved dramatically compared to that reported in
the past.2,8 In Australia, the data on similar patients are very
limited. Worldwide, there have been few studies on the
incidence and spectrum of causative microorganisms.1
The infection rate of bacterial infections in this cohort was
comparable to that found in other similar cohorts interna-
tionally, such as in Taiwan, but was lower than rates in
Israel.3,4 The variations may relate to differences in meth-
odology and the types of infections identified in each study.
The spectrum of infections was more similar to that found in
studies from Asia than to studies from the Middle East with K.
pneumoniae being a predominant pathogen in this Australian
cohort.1,3 The similarities and differences to other cohorts
may reflect geographical patterns of migration to Australia.
Some authors have postulated that this may also be linked
with improved chelation results in patients.3 The results from
our study highlight the importance of early diagnosis of K.
pneumoniae bacteremia and soft tissue and visceral infec-
tions in this population.
The skin was a common site of infection and this was likely
due to subcutaneous administration of DFO. The prevalence
of skin infections was higher than in similar cohorts and may
represent a break in sterile technique or infection suscept-
ibility.3,4
The incidence of invasive pneumococcal disease (IPD) in
Australia is relatively low and currently 23PPV is recom-
mended every five years for all asplenic patients.9 Most
individuals in this study cohort had received at least one
23PPV vaccination, in line with currently accepted clinical
recommendations. The duration of protection from infection
beyond the recommended five-year re-vaccination schedule
in asplenic individuals is not known. The heptavalent pneu-
mococcal conjugate vaccine (7PCV) may provide a novel
intervention in poor responders.10
Meningococcal infections were not recorded in this
cohort. Current vaccination guidelines recommend menin-
gococcal quadrivalent polysaccharide vaccination for hypos-
plenic/asplenic patients in or traveling to high risk/endemic
countries.5,6 Similarly, Hib vaccination should be offered to
all asplenic patients; however, timing of revaccination isunclear in this population, with lower post-vaccination-spe-
cific serum titers of antibodies compared with controls.6,11
The medical records in this cohort revealed limited infor-
mation on patient vaccination from childhood and from pri-
mary care physicians. The need for patients to be aware of the
increased infection riskassociatedwithaspleniahaspreviously
been demonstrated in a UK study where 84% of patients were
not aware of the association between asplenia and the
increased risk of sepsis.12 In a recent report from Canada,
Brigden et al. showed that only 21% of post-splenectomy
discharge summaries recorded vaccination status.13 Record
keeping improvements in the form of a centralized database
and greater emphasis on patient education about the impor-
tance of vaccination are needed, in order to avoid unnecessary
vaccination and to ensure appropriate vaccine coverage.14
Another infectious source of chronic morbidity in these
patients is blood-borne infections. In terms of these infec-
tions, Australia is regarded as a low prevalence nation, with
prevalence rates of 0.5%, 0.8%, and 0.0008%, for hepatitis B,
hepatitis C, and HIV, respectively.15—17 These patients experi-
ence a higher prevalence of these blood-borne infections,
supporting the current evidence that patients with hemoglo-
binopathies requiring transfusion should have their immunity
to hepatitis B determined, and where the lack of immunity is
documented, hepatitis B vaccination should be offered.6
Hepatocellular carcinoma (HCC), or hepatoma secondary
to hepatitis C and B, has previously been reported in patients
with thalassemia syndromes.18,19 Infection rates in our
cohort suggest that this may become a significant issue in
the future, underlining the importance of regular monitoring
of liver function tests and imaging.
This study has limitations, as the design was retrospective
and did not accommodate for vaccinations of patients with
functional hyposplenia, such as sickle cell disease. This will
have affected the relative rate of vaccinations based on a
surgical asplenia definition. The size of the cohort was also
not likely to provide sufficient power for the difference in
deaths between splenectomized and non-splenectomized
groups. These obstacles may be overcome in larger prospec-
tive studies with a consistent definition of hyposplenia based
on radionuclide scanning.13,20
Overall, survival of transfusion-dependent patients is
improving, but they remain susceptible to infections.1,8,18,19
There is a need for improved evidence-based guidelines for
continued vaccination scheduling, antibiotic prophylaxis,
and surveillance. Registers of vaccination status and the
development and delivery of educational information that
focuses on infection risk should be important tools to mini-
mize morbidity and mortality in this vulnerable population.
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